The Life Sciences team advised Axcella Health Inc. on the closing of its $71.4 million initial public offering of 3,571,428 shares of its common stock at a price to the public of $20.00 per share. Axcella’s shares began trading on The Nasdaq Global Market on May 9, 2019 under the ticker symbol “AXLA.”
Axcella is a biotechnology company pioneering the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Axcella’s AXA Candidates are generated from our proprietary, human-focused AXA Development Platform and harness the power of endogenous metabolic modulators, a broad family of molecules that fundamentally impact and regulate human metabolism.
The Goodwin team was led by partners Kingsley Taft and Laurie Burlingame and associate Carly Ward who handled all corporate aspects of the offering with assistance from partner Sarah Bock and associate James Devendorf (ERISA), partner Bradford Smith (Labor & Employment), partners Julie Tibbets and Joanne Gray and associates Steven Tjoe and Amanda Russo (FDA), partner Brian Fairchild (IP), partner Roger Cohen and associate Bryna Shmerling (Healthcare) and paralegals Pam Finan and Nathan Needle.
For additional details on the offering, please read the press release.